 "Dr Reddy's launches pramipexole dihydrochloride ER tablet in US")
Hyderabad-based Dr Reddy's Laboratories Limited has launched pramipexole dihydrochloride extended-release (ER) tablets of 0.375 mg, 0.75 mg, 3 mg, 4.5 mg, in the US market on August 11, 2015 following the approval by the US Food and Drug Administration (FDA).
Pramipexole dihydrochloride extended-release tablet, a therapeutic equivalent generic version of Mirapex ER owned by Boehringer Ingelheim, is used to treat symptoms of Parkinson's disease.
As per IMS Health, Mirapex ER brand and generic had sales of approximately $ 48.3 million in the US for the most recent twelve months ending in June, 2015.
Dr Reddy's pramipexole dihydrochloride ER tablets are available in bottle count sizes of 30.
Pramipexole dihydrochloride extended-release tablet, a therapeutic equivalent generic version of Mirapex ER owned by Boehringer Ingelheim, is used to treat symptoms of Parkinson's disease.
As per IMS Health, Mirapex ER brand and generic had sales of approximately $ 48.3 million in the US for the most recent twelve months ending in June, 2015.
Dr Reddy's pramipexole dihydrochloride ER tablets are available in bottle count sizes of 30.